CD8A and non-small cell lung carcinoma: Moreover, cisplatin can increase the infiltration of CD8+ T cells via activating cGAS-STING signaling in K-ras-driven tumor cells (77), and enhance the killing effects of CD8+ T cells through Fas/Fas ligand interactions in NSCLC mouse model (89), which may provide an inflammatory environment to enhance the anti-tumor activity of ICIs.